Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2008

Open Access 01-02-2008 | Research article

Gene expression analyses in breast cancer epidemiology: the Norwegian Women and Cancer postgenome cohort study

Authors: Vanessa Dumeaux, Anne-Lise Børresen-Dale, Jan-Ole Frantzen, Merethe Kumle, Vessela N Kristensen, Eiliv Lund

Published in: Breast Cancer Research | Issue 1/2008

Login to get access

Abstract

Introduction

The introduction of high-throughput technologies, also called -omics technologies, into epidemiology has raised the need for high-quality observational studies to reduce several sources of error and bias.

Methods

The Norwegian Women and Cancer (NOWAC) postgenome cohort study consists of approximately 50,000 women born between 1943 and 1957 who gave blood samples between 2003 and 2006 and filled out a two-page questionnaire. Blood was collected in such a way that RNA is preserved and can be used for gene expression analyses. The women are part of the NOWAC study consisting of 172,471 women 30 to 70 years of age at recruitment from 1991 to 2006 who answered one to three questionnaires on diet, medication use, and lifestyle. In collaboration with the Norwegian Breast Cancer Group, every NOWAC participant born between 1943 and 1957 who is admitted to a collaborating hospital for a diagnostic biopsy or for surgery of breast cancer will be asked to donate a tumor biopsy and two blood samples. In parallel, at least three controls are approached for each breast cancer case in order to obtain blood samples from at least two controls per case. The controls are drawn at random from NOWAC matched by time of follow-up and age. In addition, 400 normal breast tissues as well as blood samples will be collected among healthy women participating at the Norwegian Mammography Screening program at the Breast Imaging Center at the University Hospital of North-Norway, Tromsø.

Results

The NOWAC postgenome cohort offers a unique opportunity (a) to study blood-derived gene expression profiles as a diagnostic test for breast cancer in a nested case-control design with adjustment for confounding factors related to different exposures, (b) to improve the reliability and accuracy of this approach by adjusting for an individual's genotype (for example, variants in genes coding for hormone and drug-metabolizing and detoxifying enzymes), (c) to study gene expression profiles from peripheral blood as surrogate tissue to biomonitor defined exposure (for example, hormone) and its association with disease risk (that is, breast cancer), and (d) to study gene variants (single nucleotide polymorphisms and copy number variations) and environmental exposure (endogenous and exogenous hormones) and their influence on the incidence of different molecular subtypes of breast cancer.

Conclusion

The NOWAC postgenome cohort combining a valid epidemiological approach with richness of biological samples should make an important contribution to the study of the etiology and system biology of breast cancer.
Appendix
Available only for authorised users
Literature
1.
Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, WHO International Agency for Research on Cancer: Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol. 2005, 6: 552-553. 10.1016/S1470-2045(05)70273-4.CrossRefPubMed
2.
Ransohoff DF: Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer. 2005, 5: 142-149. 10.1038/nrc1550.CrossRefPubMed
3.
Wild CP: Complementing the genome with an 'exposome': the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev. 2005, 14: 1847-1850. 10.1158/1055-9965.EPI-05-0456.CrossRefPubMed
4.
Lund E, Dumeaux V, Braaten T, Hjartåker A, Engeset D, Skeie G, Kumle M: Cohort profile: The Norwegian Women and Cancer Study – NOWAC – Kvinner og kreft. Int J Epidemiol. 2008, 37: 36-41. 10.1093/ije/dym137.CrossRefPubMed
5.
6.
Lund E, Kumle M, Braaten T, Hjartaker A, Bakken K, Eggen E, Gram TI: External validity in a population-based national prospective study – the Norwegian Women and Cancer Study (NOWAC). Cancer Causes Control. 2003, 14: 1001-1008. 10.1023/B:CACO.0000007982.18311.2e.CrossRefPubMed
7.
Lunde AS, Lundeborg S, Lettenstrom GS, Thygesen L, Huebner J: The person-number systems of Sweden, Norway, Denmark, and Israel. Vital Health Stat 2. 1980, 2: 1-59.
8.
9.
Ellis M, Davis N, Coop A, Liu M, Schumaker L, Lee RY, Srikanchana R, Russell CG, Singh B, Miller WR, Stearns V, Pennanen M, Tsangaris T, Gallagher A, Liu A, Zwart A, Hayes DF, Lippman ME, Wang Y, Clarke R: Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. Clin Cancer Res. 2002, 8: 1155-1166.PubMed
10.
Slimani N, Kaaks R, Ferrari P, Casagrande C, Clavel-Chapelon F, Lotze G, Kroke A, Trichopoulos D, Trichopoulou A, Lauria C, Bellegotti M, Ocké MC, Peeters PH, Engeset D, Lund E, Agudo A, Larrañaga N, Mattisson I, Andren C, Johansson I, Davey G, Welch AA, Overvad K, Tjønneland A, Van Staveren WA, Saracci R, Riboli E: European Prospective Investigation into Cancer and Nutrition (EPIC) calibration study: rationale, design and population characteristics. Public Health Nutr. 2002, 5: 1125-1145. 10.1079/PHN2002395.CrossRefPubMed
11.
Parr CL, Veierod MB, Laake P, Lund E, Hjartaker A: Test-retest reproducibility of a food frequency questionnaire (FFQ) and estimated effects on disease risk in the Norwegian Women and Cancer Study (NOWAC). Nutr J. 2006, 5: 4-10.1186/1475-2891-5-4.CrossRefPubMedPubMedCentral
12.
Hjartåker A, Andersen LF, Lund E: Comparison of diet measures from a food-frequency questionnaire with measures from repeated 24-hour dietary recalls. The Norwegian Women and Cancer Study. Public Health Nutr. 2007, 10: 1094-1103. 10.1017/S1368980007702872.CrossRefPubMed
13.
Waaseth M, Bakken K, Dumeaux V, Olsen KS, Rylander C, Figenschau Y, Lund E: Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer Postgenome Cohort – a cross-sectional analysis. BMC Womens Health. 2008, 8: 1-10.1186/1472-6874-8-1.CrossRefPubMedPubMedCentral
14.
Debey S, Schoenbeck U, Hellmich M, Gathof BS, Pillai R, Zander T, Schultze JL: Comparison of different isolation techniques prior gene expression profiling of blood derived cells: impact on physiological responses, on overall expression and the role of different cell types. Pharmacogenomics J. 2004, 4: 193-207. 10.1038/sj.tpj.6500240.CrossRefPubMed
15.
Dumeaux V, Lund E, Børresen-Dale AL: Comparison of globin RNA processing methods for genome-wide transcriptome analysis from whole blood. Biomarkers in Medicine. 2008, 2: 11-21. 10.2217/17520363.2.1.11.CrossRefPubMed
16.
17.
18.
Debey S, Zander T, Brors B, Popov A, Eils R, Schultze JL: A highly standardized, robust, and cost-effective method for genome-wide transcriptome analysis of peripheral blood applicable to large-scale clinical trials. Genomics. 2006, 87: 653-664. 10.1016/j.ygeno.2005.11.010.CrossRefPubMed
19.
Liu J, Walter E, Stenger D, Thach D: Effects of globin mRNA reduction methods on gene expression profiles from whole blood. J Mol Diagn. 2006, 8: 551-558. 10.2353/jmoldx.2006.060021.CrossRefPubMedPubMedCentral
20.
21.
Li L, Ying L, Naesens M, Xiao W, Sigdel T, Hsieh S, Martin J, Chen R, Liu K, Mindrinos M, Davis R, Sarwal M: Interference of globin genes with biomarker discovery for allograft rejection in peripheral blood samples. Physiol Genomics. 2008, 32: 190-197.CrossRefPubMed
22.
Dumeaux V, Johansen J, Borresen-Dale AL, Lund E: Gene expression profiling of whole-blood samples from women exposed to hormone replacement therapy. Mol Cancer Ther. 2006, 5: 868-876. 10.1158/1535-7163.MCT-05-0329.CrossRefPubMed
23.
Novoradovskaya N, Whitfield ML, Basehore LS, Novoradovsky A, Pesich R, Usary J, Karaca M, Wong WK, Aprelikova O, Fero M, Perou CM, Botstein D, Braman J: Universal Reference RNA as a standard for microarray experiments. BMC Genomics. 2004, 5: 20-10.1186/1471-2164-5-20.CrossRefPubMedPubMedCentral
24.
Fare TL, Coffey EM, Dai H, He YD, Kessler DA, Kilian KA, Koch JE, LeProust E, Marton MJ, Meyer MR, Stoughton RB, Tokiwa GY, Wang Y: Effects of atmospheric ozone on microarray data quality. Anal Chem. 2003, 75: 4672-4675. 10.1021/ac034241b.CrossRefPubMed
25.
Hindle WH, Davis L, Wright D: Clinical value of mammography for symptomatic women 35 years of age and younger. Am J Obstet Gynecol. 1999, 180: 1484-1490. 10.1016/S0002-9378(99)70043-8.CrossRefPubMed
26.
Lannin DR, Harris RP, Swanson FH, Edwards MS, Swanson MS, Pories WJ: Difficulties in diagnosis of carcinoma of the breast in patients less than fifty years of age. Surg Gynecol Obstet. 1993, 177: 457-462.PubMed
27.
Barnes DM, Bartkova J, Camplejohn RS, Gullick WJ, Smith PJ, Millis RR: Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?. Eur J Cancer. 1992, 28: 644-648. 10.1016/S0959-8049(05)80117-0.CrossRefPubMed
28.
Zahl PH, Maehlen J: Model of outcomes of screening mammography: spontaneous regression of breast cancer may not be uncommon. BMJ. 2005, 331: 350-10.1136/bmj.331.7512.350-a.CrossRefPubMedPubMedCentral
29.
Twine NC, Stover JA, Marshall B, Dukart G, Hidalgo M, Stadler W, Logan T, Dutcher J, Hudes G, Dorner AJ, Slonim DK, Trepicchio WL, Burczynski ME: Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res. 2003, 63: 6069-6075.PubMed
30.
Tang Y, Nee AC, Lu A, Ran R, Sharp FR: Blood genomic expression profile for neuronal injury. J Cereb Blood Flow Metab. 2003, 23: 310-319. 10.1097/00004647-200303000-00006.CrossRefPubMed
31.
Gladkevich A, Kauffman HF, Korf J: Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2004, 28: 559-576. 10.1016/j.pnpbp.2004.01.009.CrossRefPubMed
32.
Achiron A, Gurevich M, Friedman N, Kaminski N, Mandel M: Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann Neurol. 2004, 55: 410-417. 10.1002/ana.20008.CrossRefPubMed
33.
Sharma P, Sahni NS, Tibshirani R, Skaane P, Urdal P, Berghagen H, Jensen M, Kristiansen L, Moen C, Sharma P, Zaka A, Arnes J, Sauer T, Akslen LA, Schlichting E, Børresen-Dale AL, Lönneborg A: Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Res. 2005, 7: R634-R644. 10.1186/bcr1203.CrossRefPubMedPubMedCentral
34.
Burczynski ME, Twine NC, Dukart G, Marshall B, Hidalgo M, Stadler WM, Logan T, Dutcher J, Hudes G, Trepicchio WL, Strahs A, Immermann F, Slonim DK, Dorner AJ: Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res. 2005, 11: 1181-1189.PubMed
35.
Bakken K, Alsaker E, Eggen AE, Lund E: Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer. 2004, 112: 130-134. 10.1002/ijc.20389.CrossRefPubMed
36.
Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R, SEARCH collaborators, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, Peto J, et al: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007, 447: 1087-1093. 10.1038/nature05887.CrossRefPubMedPubMedCentral
37.
Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF, Hoover RN, Thomas G, Chanock SJ: A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007, 39: 870-874. 10.1038/ng2075.CrossRefPubMedPubMedCentral
38.
Nordgard SH, Johansen FE, Alnæs GI, Naume B, Børresen-Dale AL, Kristensen VN: Genes harbouring susceptibility SNPs are differentially expressed in the breast cancer subtypes. Breast Cancer Res. 2007, 9: 113-10.1186/bcr1784.CrossRefPubMedPubMedCentral
39.
Kristensen VN, Edvardsen H, Tsalenko A, Nordgard SH, Sørlie T, Sharan R, Vailaya A, Ben-Dor A, Lønning PE, Lien S, Omholt S, Syvänen AC, Yakhini Z, Børresen-Dale AL: Genetic variation in putative regulatory loci controlling gene expression in breast cancer. Proc Natl Acad Sci USA. 2006, 103: 7735-7740. 10.1073/pnas.0601893103.CrossRefPubMedPubMedCentral
40.
Rockett JC, Burczynski ME, Fornace AJ, Herrmann PC, Krawetz SA, Dix DJ: Surrogate tissue analysis: monitoring toxicant exposure and health status of inaccessible tissues through the analysis of accessible tissues and cells. Toxicol Appl Pharmacol. 2004, 194: 189-199. 10.1016/j.taap.2003.09.005.CrossRefPubMed
41.
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral
42.
Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM: Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2007
43.
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003, 100: 8418-8423. 10.1073/pnas.0932692100.CrossRefPubMedPubMedCentral
44.
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.CrossRefPubMed
45.
Langerod AA, Zhao HH, Borgan OO, Nesland JJ, Bukholm II, Ikdahl TT, Kaaresen RR, Borresen-Dale AL, Jeffrey SS: TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res. 2007, 9: R30-10.1186/bcr1675.CrossRefPubMedPubMedCentral
46.
Evans DM, Marchini J, Morris AP, Cardon LR: Two-stage two-locus models in genome-wide association. PLoS Genet. 2006, 2: e157-10.1371/journal.pgen.0020157.CrossRefPubMedPubMedCentral
47.
Vineis P, Schulte P, McMichael AJ: Misconceptions about the use of genetic tests in populations. Lancet. 2001, 357: 709-712. 10.1016/S0140-6736(00)04136-2.CrossRefPubMed
48.
Hunter DJ, Thomas G, Hoover RN, Chanock SJ: Scanning the horizon: what is the future of genome-wide association studies in accelerating discoveries in cancer etiology and prevention?. Cancer Causes Control. 2007, 18: 479-484. 10.1007/s10552-007-0118-y.CrossRefPubMed
Metadata
Title
Gene expression analyses in breast cancer epidemiology: the Norwegian Women and Cancer postgenome cohort study
Authors
Vanessa Dumeaux
Anne-Lise Børresen-Dale
Jan-Ole Frantzen
Merethe Kumle
Vessela N Kristensen
Eiliv Lund
Publication date
01-02-2008
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2008
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1859

Other articles of this Issue 1/2008

Breast Cancer Research 1/2008 Go to the issue

Research article

Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study

Review

Re-evaluation of mammary stem cell biology based on in vivotransplantation

Research article

Basal cytokeratins in breast tumours among BRCA1, BRCA2and mutation-negative breast cancer families

Research article

Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells

Editorial

Prognostic ability of a panel of immunohistochemistry markers – retailoring of an 'old solution'

Research article

Brca1 breast tumors contain distinct CD44+/CD24- and CD133+cells with cancer stem cell characteristics
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits